Amedisys (NASDAQ:AMED) Price Target Raised to $150.00

Amedisys (NASDAQ:AMED) had its price objective boosted by Oppenheimer from $140.00 to $150.00 in a report released on Thursday, The Fly reports.

Other equities analysts have also recently issued reports about the company. BidaskClub raised Amedisys from a buy rating to a strong-buy rating in a report on Friday, July 26th. Raymond James increased their price target on Amedisys from $140.00 to $144.00 and gave the company an outperform rating in a report on Monday, July 15th. Jefferies Financial Group set a $150.00 price target on Amedisys and gave the company a buy rating in a report on Monday, July 8th. Finally, ValuEngine raised Amedisys from a hold rating to a buy rating in a report on Saturday, June 22nd. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $135.55.

AMED stock traded down $0.05 during midday trading on Thursday, hitting $135.01. The company’s stock had a trading volume of 419,435 shares, compared to its average volume of 360,816. The stock has a market capitalization of $4.33 billion, a P/E ratio of 37.19, a PEG ratio of 1.67 and a beta of 1.41. Amedisys has a 12 month low of $97.38 and a 12 month high of $141.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.91 and a current ratio of 0.88. The business has a 50-day simple moving average of $124.99.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 31st. The health services provider reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.24. The business had revenue of $492.98 million for the quarter, compared to analysts’ expectations of $489.66 million. Amedisys had a return on equity of 27.23% and a net margin of 6.84%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.00 EPS. On average, equities analysts predict that Amedisys will post 4.1 earnings per share for the current year.

In other news, insider Michael Paul North sold 10,067 shares of the company’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $130.00, for a total value of $1,308,710.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David L. Kemmerly sold 5,000 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $118.20, for a total value of $591,000.00. The disclosure for this sale can be found here. Insiders sold a total of 56,278 shares of company stock valued at $6,673,207 over the last 90 days. 2.90% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. Riverbridge Partners LLC purchased a new stake in shares of Amedisys in the 2nd quarter worth $80,465,000. Norges Bank purchased a new stake in Amedisys in the 4th quarter worth $68,342,000. Geode Capital Management LLC increased its stake in Amedisys by 23.4% in the 4th quarter. Geode Capital Management LLC now owns 429,999 shares of the health services provider’s stock worth $50,357,000 after buying an additional 81,573 shares in the last quarter. FMR LLC increased its stake in Amedisys by 13.4% in the 1st quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock worth $45,703,000 after buying an additional 43,844 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Amedisys by 12.1% in the 4th quarter. Deutsche Bank AG now owns 319,075 shares of the health services provider’s stock worth $37,365,000 after buying an additional 34,553 shares in the last quarter. Hedge funds and other institutional investors own 88.10% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Read More: What is meant by holder of record?

The Fly

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.